MediWound Ltd. (MDWD)

Nasdaq Pharmaceutical Pharmaceutical Chemicals SIC: 2833
D
Pipeline Grade

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

DateEventDrug
2026-12-01 Phase3 Readout

Active Clinical Trials (2)

NCT #TitlePhaseStatusEnrollment
NCT06568627 A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE) PHASE3 Recruiting 216
NCT05157763 A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma PHASE2 Recruiting 32

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis